Ladiratuzumab vedotin
Product Specifications
Specifications
4.16
Synonyms
SGN-LIV1A, Anti-LIV-1 ADC
Target
Antibody-Drug Conjugate
Applications
Others
Additionnal Information
Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas.
Storage Conditions
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC740226-100 1x 100 µL
Pmel17 / gp100 / SILV (NKI-beteb), CF740 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880178-500 1x 500 µL
CD50 (ICAM-3) (186-2G9), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC880257-500 1x 500 µL
Cytokeratin, HMW (AE-3), CF488A conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401138-100 1x 100 µL
WT1 (Wilm's Tumor 1) (WT1/857 + 6F-H2), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details